133117-06-3

Upstream product

• 133095-96-2 (S)-5-(3-Methoxy-5-methylsulfanyl-4-propoxy-phenyl)-dihydro-furan-2-one 
• 133095-93-9 (S)-4-Hydroxy-4-(3-iodo-5-methoxy-4-propoxy-phenyl)-butyric acid tert-butyl ester 
• 106331-89-9 3-methoxy-4-n-propyloxy-5-iodobenzaldehyde 
• 133095-92-8 4-(3-Iodo-5-methoxy-4-propoxy-phenyl)-4-oxo-butyric acid tert-butyl ester 
• 133095-94-0 (S)-4-Hydroxy-4-(3-iodo-5-methoxy-4-propoxy-phenyl)-butyric acid 
• 133095-95-1 4[3-Methoxy-4-n-propyloxy-5-iodophenyl]-4S-butyrolactone 
• 5438-36-8 5-iodovaniline 

Downstream Products

• 133095-97-3 (S)-5-(3-Methanesulfonyl-5-methoxy-4-propoxy-phenyl)-tetrahydro-furan-2-ol 
• 133095-99-5 (2S,5S)-2-(3-Methanesulfonyl-5-methoxy-4-propoxy-phenyl)-5-(2,3,4-trimethoxy-phenyl)-tetrahydro-furan 
• 133095-90-6 (S)-2-Bromo-5-(3-methanesulfonyl-5-methoxy-4-propoxy-phenyl)-tetrahydro-furan 
• 116781-15-8 (-)-L 659989 
• 121702-60-1 L 662418 

Relevant academic research and scientific papers

Conversion of a silylated hemiacetal into an α-bromoether using trimethylsilylbromide. Synthesis of platelet activating factor antagonist L-659,989

An efficient synthesis of platelet activating factor antagonist L-659,989 has been achieved in ten steps from commercially available 5-iodovanillin. The key transformation converts a silylated hemi-acetal into an α-bromoether followed by a highly stereose